Hib-meningococcal vaccine groups A and C polysaccharide conjugate - Chongqing Zhifei Biological Products

Drug Profile

Hib-meningococcal vaccine groups A and C polysaccharide conjugate - Chongqing Zhifei Biological Products

Alternative Names: HibACon; MenAC-Hib - Chongqing Zhifei Biological Products; MenAC-Hib polysaccharide conjugate vaccine

Latest Information Update: 06 Oct 2016

Price : $50

At a glance

  • Originator Chongqing Zhifei Biological Products
  • Class Haemophilus vaccines; Meningococcal vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Haemophilus infections; Meningococcal group A infections; Meningococcal group C infections

Most Recent Events

  • 01 Aug 2016 Phase-I/II clinical trials in Haemophilus infections, Meningococcal group A infections and Meningococcal group C infections (Prevention, In infants) in China (IM) (NCT02919293)
  • 05 Jun 2015 Phase III development is ongoing in China
  • 30 Oct 2012 Phase-III clinical trials in Haemophilus infections (Prevention) in China (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top